Online inquiry

IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2150MR)

This product GTTS-WQ2150MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2150MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12065MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ2927MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ7466MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ12639MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ9167MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ10137MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ6379MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ14379MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA r-hTBP-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW